Advertisement

Topics

Pfizer Sales Fall Short as Pressure Mounts to Make a Deal

09:36 EDT 1 Aug 2017 | Topix

Investors are watching Pfizer's next move after several quarters of lackluster results, dragged down by its top-selling Prevnar vaccination shots and sales of products that are facing loss of exclusivity, like the erectile dysfunction treatment Viagra. Newer drugs, like blockbuster breast cancer drug Ibrance, showed strength last quarter, but it wasn't enough to lift overall sales.

Original Article: Pfizer Sales Fall Short as Pressure Mounts to Make a Deal

NEXT ARTICLE

More From BioPortfolio on "Pfizer Sales Fall Short as Pressure Mounts to Make a Deal"

Quick Search
Advertisement
 

Relevant Topics

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...